ReviewOncoimmunology2014
Consensus guidelines for the detection of immunogenic cell death.
Open access · goldAbstract readReview
In one paragraph
Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 497 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
497citing papers in PubMed, 2 pooled it
26.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
497 citing papers in PubMed, 2 syntheses or guidelines pooled it, 807 citations in OpenAlex.
- Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications.Frontiers in oncology · 2026Pooled it
- Calreticulin Expression in Human Carcinomas: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Igniting antitumour immunity with cancer cell pyroptosis.Nature reviews. Cancer · 2026Review
- Magnetically Guided Macrophage Immunobots Coordinate Iron-Metabolic Cascades and Immunogenic Ferroptosis for Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.Cell reports. Medicine · 2026Article
- Inhibition of KDEL Receptors Remodels the Tumor Microenvironment for T Cell Independent Tumor Regression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Context-Dependent Mechanisms of Oncologic Photodynamic Therapy: A Framework Linking Treatment Parameters to Cellular, Vascular, and Immune Responses.International journal of molecular sciences · 2026Review
- Recent advances in near-infrared dye conjugates for near-infrared photoimmunotherapy (NIR-PIT): enhancing therapeutic efficacy and immune mechanisms.RSC chemical biology · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Plant-Derived Natural Products and Selective Apoptosis: A Cancer-Cell Vulnerability-State Framework from Redox Imbalance to Membrane-Ion Dysregulation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- Navitoclax-encapsulated dual pH-responsive copolymeric nanoparticles improves hepatocellular carcinoma treatment with induction of apoptosis and immune activation.Journal of nanobiotechnology · 2026Article
- Nanosecond Electric Pulses as a Novel In Situ Vaccination Strategy for Cancer Treatment: Mechanisms, Challenges and Prospects.Vaccines · 2026Review
- OT-55 reshapes tolerogenic BH3-mimetic-induced apoptosis toward immunogenic cell death in acute myeloid leukemia, potentiating PD-1/Tim-3 blockade.Cell death & disease · 2026Article
- Golden immunity: gold complexes as emerging triggers of immunogenic cell death.Chemical science · 2026Review
- From Innate Immunity to Cancer Therapy: Antimicrobial Peptides as Emerging Anticancer Agents.International journal of molecular sciences · 2026Review
- Weekly measurement of HMGB1 during neoadjuvant chemoradiotherapy in rectal cancer patients: correlations with MRI response and ctDNA.Radiology and oncology · 2026Article
- Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells.Science advances · 2026Article
- Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy.Nature communications · 2026Article
- Mass Spectrometry-Driven Proteomic Biomarkers for Serum-Based Detection of Pancreatic Ductal Adenocarcinoma and Intraductal Papillary Mucinous Neoplasm-Associated Invasive Carcinoma.Cancer medicine · 2026Article
437 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
82 authors at 20 institutions in 23 countries.
Oliver KeppEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
Laura SenovillaINSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1015 ; Villejuif, France.
Ilio VitaleRegina Elena National Cancer Institute ; Rome, Italy.
Erika VacchelliEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Sandy AdjemianEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Molecular Cell Biology Laboratory; Department of Immunology; Institute of Biomedical Sciences; University of São Paulo ; São Paulo, Brazil.
Patrizia AgostinisCell Death Research and Therapy (CDRT) Laboratory; Department of Cellular and Molecular Medicine; University of Leuven ; Leuven, Belgium.
Lionel ApetohINSERM; UMR866 ; Dijon, France ; Centre Georges François Leclerc ; Dijon, France ; Université de Bourgogne ; Dijon, France.
Fernando ArandaEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Vincenzo BarnabaDepartement of Internal Medicine and Medical Sciences; University of Rome La Sapienza ; Rome, Italy ; Istituto Pasteur; Fondazione Cenci Bolognetti ; Rome, Italy.
Norma BloyEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Laura BracciDepartment of Hematology; Oncology and Molecular Medicine; Istituto Superiore di Sanità (ISS) ; Rome, Italy.
Karine BreckpotLaboratory of Molecular and Cellular Therapy (LMCT); Department of Biomedical Sciences Medical School of the Free University of Brussels (VUB) ; Jette, Belgium.
David BroughFaculty of Life Sciences; University of Manchester ; Manchester, UK.
Aitziber BuquéEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Maria G CastroDepartment of Neurosurgery and Cell and Developmental Biology; University of Michigan School of Medicine ; Ann Arbor, MI USA.
Mara CironeDepartment of Experimental Medicine; University of Rome La Sapienza ; Rome, Italy.
Maria I ColomboLaboratorio de Biología Celular y Molecular; Instituto de Histología y Embriología (IHEM); Facultad de Ciencias Médicas; Universidad Nacional de Cuyo; CONICET ; Mendoza, Argentina.
Isabelle CremerINSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Equipe 13; Center de Recherche des Cordeliers ; Paris, France.
Sandra DemariaDepartment of Pathology; New York University School of Medicine ; New York, NY USA.
Luciana DiniDepartment of Biological and Environmental Science and Technology (DiSTeBA); University of Salento ; Lecce, Italy.
Aristides G EliopoulosMolecular and Cellular Biology Laboratory; Division of Basic Sciences; University of Crete Medical School ; Heraklion, Greece ; Institute of Molecular Biology and Biotechnology; Foundation of Research and Technology - Hellas ; Heraklion, Greece.
Alberto FaggioniDepartment of Experimental Medicine; University of Rome La Sapienza ; Rome, Italy.
Silvia C FormentiDepartment of Radiation Oncology; NewYork University School of Medicine and Langone Medical Center ; New York, NY USA.
Jitka FučíkováDepartment of Immunology; 2nd Faculty of Medicine and University Hospital Motol, Charles University ; Prague, Czech Republic ; Sotio ; Prague, Czech Republic.
Lucia GabrieleDepartment of Hematology; Oncology and Molecular Medicine; Istituto Superiore di Sanità (ISS) ; Rome, Italy.
Udo S GaiplDepartment of Radiation Oncology; University Hospital Erlangen; University of Erlangen-Nürnberg ; Erlangen, Germany.
Jérôme GalonINSERM; U1138 ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Laboratory of Integrative Cancer Immunology; Center de Recherche des Cordeliers ; Paris, France.
Abhishek GargCell Death Research and Therapy (CDRT) Laboratory; Department of Cellular and Molecular Medicine; University of Leuven ; Leuven, Belgium.
François GhiringhelliINSERM; UMR866 ; Dijon, France ; Centre Georges François Leclerc ; Dijon, France ; Université de Bourgogne ; Dijon, France.
Nathalia A GieseEuropean Pancreas Center; Department of Surgery; University Hospital Heidelberg ; Heidelberg, Germany.
Zong Sheng GuoDepartment of Surgery; University of Pittsburgh ; Pittsburgh, PA USA.
Akseli HemminkiCancer Gene Therapy Group; Transplantation laboratory; Haartman Institute; University of Helsinki ; Helsinki, Finland.
Martin HerrmannDepartment of Internal Medicine 3; University of Erlangen-Nuremberg ; Erlangen, Germany.
James W HodgeLaboratory of Tumor Immunology and Biology; Center for Cancer Research; National Cancer Institute (NCI), National Institutes of Health (NIH) ; Bethesda, MD USA.
Stefan HoldenriederInstitute of Clinical Chemistry and Clinical Pharmacology; University Hospital Bonn ; Bonn, Germany.
Jamie HoneychurchFaculty of Medical and Human Sciences, Institute of Cancer Studies; Manchester Academic Health Sciences Center; University of Manchester ; Manchester, UK.
Hong-Min HuCancer Research and Biotherapy Center; Second Affiliated Hospital of Southeast University ; Nanjing, China ; Laboratory of Cancer Immunobiology; Earle A. Chiles Research Institute; Providence Portland Medical Center ; Portland, OR USA.
Xing HuangEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
Tim M IllidgeFaculty of Medical and Human Sciences, Institute of Cancer Studies; Manchester Academic Health Sciences Center; University of Manchester ; Manchester, UK.
Koji KonoDepartment of Surgery; National University of Singapore ; Singapore, Singapore ; Cancer Science Institute of Singapore; National University of Singapore ; Singapore, Singapore.
Mladen KorbelikBritish Columbia Cancer Agency ; Vancouver, Canada.
Dmitri V KryskoVIB Inflammation Research Center ; Ghent, Belgium ; Department of Biomedical Molecular Biology; Ghent University ; Ghent, Belgium.
Sherene LoiDivision of Cancer Medicine and Division of Research; Peter MacCallum Cancer Center; East Melbourne ; Victoria, Australia.
Pedro R LowensteinDepartment of Neurosurgery and Cell and Developmental Biology; University of Michigan School of Medicine ; Ann Arbor, MI USA.
Enrico LugliUnit of Clinical and Experimental Immunology; Humanitas Clinical and Research Center ; Milan, Italy ; Department of Medical Biotechnologies and Translational Medicine, University of Milan ; Rozzano, Italy.
Yuting MaEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Frank MadeoInstitute of Molecular Biosciences; University of Graz ; Graz, Austria.
Angelo A ManfrediUniversity Vita-Salute San Raffaele ; Milano, Italy ; San Raffaele Scientific Institute ; Milano, Italy.
Isabelle MartinsGustave Roussy Cancer Campus ; Villejuif, France ; INSERM, U1030 ; Villejuif, France ; Faculté de Médecine; Université Paris-Sud/Paris XI ; Kremlin-Bicêtre, France.
Domenico MavilioUnit of Clinical and Experimental Immunology; Humanitas Clinical and Research Center ; Milan, Italy ; Department of Medical Biotechnologies and Translational Medicine, University of Milan ; Rozzano, Italy.
Laurie MengerEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Cancer Immunology Unit, Research Department of Haematology; University College London (UCL) Cancer Institute ; London, UK.
Nicolò MerendinoDepartment of Ecological and Biological Sciences (DEB), Tuscia University ; Viterbo, Italy.
Michael MichaudEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Gregoire MignotCellular and Molecular Immunology and Endocrinology , Oniris; Nantes, France.
Karen L MossmanDepartment of Pathology and Molecular Medicine; McMaster Immunology Research Center ; Hamilton, Canada ; Institute for Infectious Disease Research; McMaster University ; Hamilton, Canada.
Gabriele MulthoffDepartment of Radiation Oncology; Klinikum rechts der Isar; Technical University of Munich ; Munich, Germany.
Rudolf OehlerComprehensive Cancer Center; Medical University of Vienna ; Vienna, Austria.
Fabio PalomboDepartement of Internal Medicine and Medical Sciences; University of Rome La Sapienza ; Rome, Italy ; Istituto Pasteur; Fondazione Cenci Bolognetti ; Rome, Italy.
Theocharis PanaretakisDepartment of Oncology-Pathology; Karolinska Institute ; Stockholm, Sweden.
Jonathan PolEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France.
Enrico ProiettiDepartment of Hematology; Oncology and Molecular Medicine; Istituto Superiore di Sanità (ISS) ; Rome, Italy.
Jean-Ehrland RicciINSERM; U1065 ; Nice, France ; Equipe "Contrôle Métabolique des Morts Cellulaires," Center Méditerranéen de Médecine Moléculaire (C3M) ; Nice, France ; Faculté de Médecine; Université de Nice Sophia Antipolis ; Nice, France ; Centre Hospitalier Universitaire de Nice ; Nice, France.
Chiara RigantiDepartment of Oncology and Subalpine Center for Research and Experimental Medicine (CeRMS); University of Turin ; Turin, Italy.
Patrizia Rovere-QueriniUniversity Vita-Salute San Raffaele ; Milano, Italy ; San Raffaele Scientific Institute ; Milano, Italy.
Anna RubartelliCell Biology Unit; Azienda Ospedaliera Universitaria San Martino ; Istituto Nazionale per la Ricerca sul Cancro ; Genova, Italy.
Antonella SistiguRegina Elena National Cancer Institute ; Rome, Italy.
Mark J SmythImmunology in Cancer and Infection Laboratory; QIMR Berghofer Medical Research Institute ; Herston, Australia ; School of Medicine, University of Queensland ; Herston, Australia.
Juergen SonnemannDepartment of Pediatric Haematology and Oncology; Jena University Hospital, Children's Clinic ; Jena, Germany.
Radek SpisekDepartment of Immunology; 2nd Faculty of Medicine and University Hospital Motol, Charles University ; Prague, Czech Republic ; Sotio ; Prague, Czech Republic.
John StaggCentre de Recherche du Center Hospitalier de l'Université de Montréal; Faculté de Pharmacie, Université de Montréal ; Montréal, Canada.
Abdul Qader SukkurwalaEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Department of Pathology, Dow International Medical College; Dow University of Health Sciences ; Karachi, Pakistan.
Eric TartourINSERM; U970 ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
Andrew ThorburnDepartment of Pharmacology; University of Colorado School of Medicine ; Aurora, CO USA.
Stephen H ThorneDepartment of Surgery; University of Pittsburgh ; Pittsburgh, PA USA.
Peter VandenabeeleVIB Inflammation Research Center ; Ghent, Belgium ; Department of Biomedical Molecular Biology; Ghent University ; Ghent, Belgium ; Methusalem Program; Ghent University ; Ghent, Belgium.
Francesca VelottiDepartment of Ecological and Biological Sciences (DEB), Tuscia University ; Viterbo, Italy.
Samuel T WorkenheDepartment of Pathology and Molecular Medicine; McMaster Immunology Research Center ; Hamilton, Canada ; Institute for Infectious Disease Research; McMaster University ; Hamilton, Canada.
Haining YangUniversity of Hawaii Cancer Center ; Honolulu, HI USA.
Wei-Xing ZongDepartment of Molecular Genetics and Microbiology; Stony Brook University ; Stony Brook, NY USA.
Laurence ZitvogelINSERM; U1015 ; Villejuif, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Centre d'Investigation Clinique Biothérapie 507 (CICBT507); Gustave Roussy Cancer Campus ; Villejuif, France.
Guido KroemerEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
Lorenzo GalluzziEquipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; INSERM; U1138 ; Paris, France ; Gustave Roussy Cancer Campus ; Villejuif, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
Inserm · FRWeatherford College · USLa Ligue Contre le Cancer · FRSapienza University of Rome · ITGhent University Hospital · BEInstitut Gustave Roussy · FRManchester Academic Health Science Centre · GBMolecular Oncology (United States) · USNational Cancer Institute · MYShanghai Cell Therapy Research Institute · CNSotio (Czechia) · CZUniversità degli Studi della Tuscia · ITUniversité de Bourgogne · FRUniversity of Pittsburgh · USAnn Arbor Center for Independent Living · USAssistance Publique – Hôpitaux de Paris · FRAzienda Ospedaliera Universitaria Policlinico "G. Martino" · ITBC Cancer Agency · CACellular Research (United States) · USCentre de Recherche des Cordeliers · FR
Funding
Vaccine and radiation for the therapy of human cancersZIABC010975 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HODGE, JAMES · 2009 to 2025
$11.0MProtein and redox homeostasis in cancer development and therapyR01CA129536 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI ZONG, WEI-XING · 2008 to 2022
$4.8MEngineering the Brain Immune System for Tumor TherapyR01NS057711 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2009 to 2013
$2.0MCrosstalk between glioma cells & immune cells in the tumor microenvironment: TherR01NS074387 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2011 to 2015
$1.9MBrain immune responses:Cellular & Molecular MechanismsR01NS061107 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2008 to 2012
$1.7MMechanisms of glioma growth and invasion novel therapeutic strategiesR01NS082311 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2017
$1.7MCancer Research UK 11335Cancer Research UK 17737NCI NIH HHS R01 CA129536NINDS NIH HHS R01 NS057711NINDS NIH HHS R01 NS061107NINDS NIH HHS R01 NS074387NINDS NIH HHS R01 NS082311
Abstract
Apoptotic cells have long been considered as intrinsically tolerogenic or unable to elicit immune responses specific for dead cell-associated antigens. However, multiple stimuli can trigger a functionally peculiar type of apoptotic demise that does not go unnoticed by the adaptive arm of the immune system, which we named "immunogenic cell death" (ICD). ICD is preceded or accompanied by the emission of a series of immunostimulatory damage-associated molecular patterns (DAMPs) in a precise spatiotemporal configuration. Several anticancer agents that have been successfully employed in the clinic for decades, including various chemotherapeutics and radiotherapy, can elicit ICD. Moreover, defects in the components that underlie the capacity of the immune system to perceive cell death as immunogenic negatively influence disease outcome among cancer patients treated with ICD inducers. Thus, ICD has profound clinical and therapeutic implications. Unfortunately, the gold-standard approach to detect ICD relies on vaccination experiments involving immunocompetent murine models and syngeneic cancer cells, an approach that is incompatible with large screening campaigns. Here, we outline strategies conceived to detect surrogate markers of ICD
Indexed as
APC, antigen-presenting cellATF6, activating transcription factor 6ATP releaseautophagyBAK1, BCL2-antagonist/killer 1BAX, BCL2-associated X proteinBCL2, B-cell CLL/lymphoma 2 proteinCALR, calreticulincalreticulinCTL, cytotoxic T lymphocyteDAMP, damage-associated molecular patternDAPI, 4′,6-diamidino-2-phenylindoleDiOC6(3), 3,3′-dihexyloxacarbocyanine iodideEIF2A, eukaryotic translation initiation factor 2Aendoplasmic reticulum stressER, endoplasmic reticulumFLT3LG, fms-related tyrosine kinase 3 ligandG3BP1, GTPase activating protein (SH3 domain) binding protein 1GFP, green fluorescent proteinH2B, histone 2BHMGB1HMGB1, high mobility group box 1HSP, heat shock proteinHSV-1, herpes simplex virus type IICD, immunogenic cell deathIFN, interferonIL, interleukinimmunotherapymember 3MOMP, mitochondrial outer membrane permeabilizationPDIA3, protein disulfide isomerase family API, propidium iodideRFP, red fluorescent proteinTLR, Toll-like receptorXBP1, X-box binding protein 1Δψm, mitochondrial transmembrane potential
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.